基于二代测序的聚（ADP-核糖）聚合酶抑制剂治疗宫颈神经内分泌癌
Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing.
作者信息
Rose Peter G, Sierk Anne
机构信息
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cleveland Clinic, United States of America.
Department of Anatomic Pathology, Cleveland Clinic, United States of America.
出版信息
Gynecol Oncol Rep. 2019 Sep 12;30:100499. doi: 10.1016/j.gore.2019.100499. eCollection 2019 Nov.
Abstract
•This case reports the treatment of neuroendocrine carcinoma of the cervix with a PARPi based on NGS.•NGS reports have demonstrated somatic mutations BRCA in neuroendocrine carcinoma of the cervix.•The use of a PARPi in neuroendocrine carcinoma of the cervix has not been previously reported.
摘要
•本病例报告了基于二代测序（NGS）使用聚（ADP-核糖）聚合酶抑制剂（PARPi）治疗宫颈神经内分泌癌的情况。
•NGS报告已证实宫颈神经内分泌癌存在BRCA体细胞突变。
•此前尚未有关于在宫颈神经内分泌癌中使用PARPi的报道。
Zotero 插件